BioLineRx Ltd. (NASDAQ: BLRX) has released encouraging data from the pharmacoeconomic study assessing the cost-effectiveness of employing experimental drug Motixafortide in combination with granulocyte colony-stimulating factor as a primary stem cell mobilizing factor relative to G-CSF alone in treating multiple myeloma patients under autologous stem cell transplantation.
Motixafortide combination with G-CSF showed meaningful benefit
IQVIA’s Global Health Economics and Outcomes Research (HEOR) team conducted the study as part of a concurrent pre-planned study with the GENESIS Phase 3 trial. Combined with the GENESIS trial’s significant and clinically important data, the findings clearly justify Motixafortide’s use.
Study findings show that when compared to G-CSF alone, adding Motixafortide to G-CSF resulted in a statistically significant decrease in health resource usage during the ASCT process. In addition, lifetime estimations demonstrate quality-adjusted-life-year improvements and a net cost savings of $17,000 compared to using G-CSF alone, based on the much higher mobilized cells number and the lower apheresis procedures number. Finally, based on established willingness-to-pay (WTP) values for healthcare payers, the study findings, together with model estimates, show that using the medication in addition to G-CSF as the standard of care in ASCT mobilization could be a cost-effective alternative in the US.
Motixafortide can lead to cost savings
CEO Philip Serlin said, “The compelling cost savings identified by this rigorously designed study strongly support the Company’s view that Motixafortide, in combination with G-CSF, can become the new standard of care as an upfront, or primary, therapy for all multiple myeloma patients undergoing autologous stem cell transplantation. Based on data from the GENESIS trial showing that nearly 90% of patients collected an optimal number of cells for transplantation following a single administration of Motixafortide and in only one apheresis session, versus less than 10% for G-CSF alone, the pharmacoeconomic study demonstrates that use of Motixafortide on top of G-CSF can save $17,000 per patient, not including the cost of Motixafortide.”
